banner-3
banner-2
banner-1
company01

About our company

What do we do?

Hebei Kejiang Biotechnology Co., LTD is an enterprise located in Shijiazhuang, the capital of Hebei Province, China. We manufacture intermediates for several API’s falling under a wide range of therapeutic categories, and also manufacture high value fine chemicals & Specialty chemicals.

Our products are sold all over the world (Europe, South America, North America, Southeast Asia and Africa), and are highly praised by customers.Our company has reasonable prices and safe and efficient transportation methods, and has a strict quality management system and high-quality after-sales service, to meet the product and purchasing needs of new and old customers.

view more

Hot products

Our products

Contact us for more sample albums

According to your needs, customize for you, and provide you with more valuable products.

INQUIRY NOW
  • Service

    Service

    Whether it is pre-sale or after-sales, we will provide you with the best service to let you know and use our products more quickly.

  • Strong technical team

    Strong technical team

    We have a strong technical team in the industry, decades of professional experience, excellent design level, creating a high-quality high-efficiency intelligent equipment.

  • Technology

    Technology

    We persist in qualities of products and control strictly the producing processes, committed to the manufacture of all types.

position_icon

Latest information

news

Peptide synthesis and equipment
Chemical synthesis method of polypeptide: Solid-phase synthesis method: In 1963, R.B. Merrifield established the solid-phase synthesis method of fixing the C-terminal of a...

Peptide synthesis and equipment

Chemical synthesis method of polypeptide: Solid-phase synthesis method: In 1963, R.B. Merrifield established the solid-phase synthesis method of fixing the C-terminal of amino acid on an insoluble resin, and then successively condensation of amino acid, extension of pept...

Society and culture

Regulatory approval Studies are ongoing into reports of sudden death, heart failure, renal failure and gastrointestinal problems. Despite a 2002 petition by Ralph Nader-founded NGO Public Citizen, the FDA made no attempts to withdraw the drug, but was part of a Senate hearing in 2005.[30] Similar...

QC Profile

In order to implement an effective QC program, an enterprise must first decide which specific standards the product or service must meet. Then the extent of QC actions must be determined -- for example, the percentage of units to be tested from each lot. Next, real-world...